Monte Rosa Therapeutics, Inc.
GLUEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Monte Rosa Therapeutics, Inc. (GLUE) is listed under Biotechnology. The $1.22B market capitalization puts GLUE squarely in small-cap range for its industry. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Market Cap
$1.22B
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-7.61
EPS (TTM)
$-1.75
EPS (Fwd)
$-1.87
ROE
-42.7%
ROA
-21.6%
Cash
$621.1M
Total Debt
$38.0M
Free CF
-$74.4M
52W Change
188.3%
Annual Financials
Cash vs Debt
Where GLUE stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, GLUE finished 28.68% below its 150-day moving average ($18.76) and 27.75% below its 200-day moving average ($18.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GLUE overbought or oversold?
At the August 31, 2026 close, GLUE's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $621.1M in cash and $38.0M in debt, GLUE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$74.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -42.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Monte Rosa Therapeutics, Inc.'s trajectory.